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Significance of this study
What is already known on this subject?
 ► Patients thought to be at increased risk of 
colorectal cancer (CRC) after adenoma removal 
are recommended surveillance by colonoscopy.
 ► The 2002 UK surveillance guidelines stratify 
patients with adenomas into low- risk, 
intermediate- risk and high- risk groups 
according to baseline adenoma characteristics, 
and recommend different surveillance 
strategies for each risk group.
 ► The evidence supporting the guidelines is 
limited. Most studies on adenoma surveillance 
predate improvements in colonoscopy quality 
and examine detection rates of advanced 
adenomas at follow- up colonoscopy rather than 
long- term risk of CRC.
 ► Adenoma surveillance currently accounts for 
20% of colonoscopies performed in the UK, 
placing enormous pressure on endoscopy 
services.
 ► Some patients may require less surveillance 
than currently recommended; however, this is 
uncertain due to the lack of high- quality data 
with CRC as the outcome.
AbSTrACT
Objective Postpolypectomy colonoscopy surveillance 
aims to prevent colorectal cancer (crc). The 2002 UK 
surveillance guidelines define low- risk, intermediate- risk 
and high- risk groups, recommending different strategies 
for each. evidence supporting the guidelines is limited. 
We examined crc incidence and effects of surveillance 
on incidence among each risk group.
Design retrospective study of 33 011 patients who 
underwent colonoscopy with adenoma removal at 17 
UK hospitals, mostly (87%) from 2000 to 2010. Patients 
were followed up through 2016. cox regression with 
time- varying covariates was used to estimate effects 
of surveillance on crc incidence adjusted for patient, 
procedural and polyp characteristics. standardised 
incidence ratios (sirs) compared incidence with that in 
the general population.
results after exclusions, 28 972 patients were available 
for analysis; 14 401 (50%) were classed as low- risk, 
11 852 (41%) as intermediate- risk and 2719 (9%) 
as high- risk. Median follow- up was 9.3 years. in the 
low- risk, intermediate- risk and high- risk groups, crc 
incidence per 100 000 person- years was 140 (95% ci 
122 to 162), 221 (195 to 251) and 366 (295 to 453), 
respectively. crc incidence was 40%–50% lower 
with a single surveillance visit than with none: hazard 
ratios (hrs) were 0.56 (95% ci 0.39 to 0.80), 0.59 
(0.43 to 0.81) and 0.49 (0.29 to 0.82) in the low- risk, 
intermediate- risk and high- risk groups, respectively. 
compared with the general population, crc incidence 
without surveillance was similar among low- risk (sir 
0.86, 95% ci 0.73 to 1.02) and intermediate- risk (1.16, 
0.97 to 1.37) patients, but higher among high- risk 
patients (1.91, 1.39 to 2.56).
Conclusion Postpolypectomy surveillance reduces crc 
risk. however, even without surveillance, crc risk in 
some low- risk and intermediate- risk patients is no higher 
than in the general population. These patients could be 
managed by screening rather than surveillance.
InTrODuCTIOn
Colorectal cancer (CRC) causes considerable 
morbidity and mortality.1 It can be prevented by 
removing adenomas, known precursors.2 Patients at 
increased risk of CRC following adenoma removal 
are recommended surveillance colonoscopy. The 
2002 UK surveillance guidelines stratify patients 
with adenomas into three risk groups,3 as do the 
European Union (EU) and US guidelines.4 5 Low- risk 
patients (with 1–2 adenomas <10 mm) are recom-
mended no surveillance or surveillance at 5–10 
years; while intermediate- risk/higher- risk patients 
(with 3–4 adenomas <10 mm or 1–2 adenomas 
with at least 1≥10 mm (UK/EU), or 3–10 adenomas 
or at least 1≥10 mm, with villous histology, or high- 
grade dysplasia (US)) are recommended 3- yearly 
surveillance. High- risk patients (with 5 or more 
adenomas <10 mm, or 3 or more adenomas with 
at least 1≥10 mm (UK), or more than 10 adenomas 
(US)) are recommended colonoscopy at 1 year or 
within 3 years before 3- yearly surveillance.
The 2002 UK guidelines were largely based on 
studies using detection rates of advanced adenomas 
(AAs) at follow- up as a proxy for CRC,3 6–9 which 
overestimates risk due to higher rates of AAs than 
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Significance of this study
What are the new findings?
 ► Among ~30 000 patients with adenomas, CRC risk remained 
elevated in only a third after baseline colonoscopy and 
polypectomy.
 ► Patients remaining at increased CRC risk included the whole 
high- risk group, in addition to intermediate- risk patients 
with an incomplete colonoscopy, adenoma with high- grade 
dysplasia or proximal polyps at baseline. Colonoscopy 
surveillance significantly reduced CRC risk in these patients.
 ► Colonoscopy surveillance also reduced CRC risk among 
the remaining two- thirds of patients, including the whole 
low- risk group and intermediate- risk patients with a 
complete baseline colonoscopy and no high- grade dysplasia 
or proximal polyps. However, even without surveillance, 
these patients had a CRC risk no higher than the general 
population.
How might it impact on clinical practice in the foreseeable 
future?
 ► Following a complete baseline colonoscopy and polypectomy, 
low- risk patients and intermediate- risk patients with no high- 
grade dysplasia or proximal polyps could be managed by 
routine screening rather than by surveillance.
 ► In England, if these patients forewent surveillance and 
instead returned to the National Health Service Bowel Cancer 
Screening Programme, numbers of surveillance colonoscopies 
could be reduced by a third.
 ► Patients returning to screening should be reminded to 
see their general practitioner if they experience any lower 
gastrointestinal symptoms.
 ► Additional long- term studies and economic evaluations are 
needed to define optimal surveillance strategies for those 
remaining at increased CRC risk following adenoma removal.
CRC.9 10 Moreover, as the guidelines were developed before 
substantial improvements in colonoscopy quality,11 such inten-
sive surveillance may no longer be necessary.
In 2004, there was a call for proposals to reassess surveillance 
requirements among intermediate- risk patients, who account for 
most surveillance colonoscopies.12 There was concern that the 
introduction of the Bowel Cancer Screening Programme (BCSP) 
in 2006 would increase demand for surveillance and overwhelm 
endoscopy services. We developed a study that examined CRC 
incidence among intermediate- risk patients over a median of 7.9 
years, identifying a higher- risk subgroup who benefited from 
surveillance and a lower- risk subgroup who could potentially 
forego surveillance.13
These findings were timely as adenoma surveillance accounts 
for 20% of colonoscopies performed in the UK and USA, placing 
great pressure on endoscopy services.14 15 Revision of the guide-
lines is required to minimise unnecessary colonoscopies while 
ensuring that patients at increased CRC risk receive surveillance. 
The present study examined CRC incidence among all three 
risk groups over a median of 9.3 years and assessed effects of 
surveillance on CRC incidence. We aimed to identify patient 
subgroups who could safely forego surveillance or receive less 
than currently recommended.
MeTHODS
Study design and participants
We conducted a retrospective study using data from 17 UK 
hospitals on patients who had adenomas removed at base-
line colonoscopy from 1984 to 2010 (mostly (87%) from 
2000 to 2010). We used this cohort for our previous study 
of intermediate- risk patients.13 16 For the present study, we 
obtained updated information on the cohort (eg, on surveil-
lance examinations, cancers and deaths). This provided longer- 
term follow- up data for the intermediate- risk group. We 
additionally examined the low- risk and high- risk groups not 
previously analysed.
Participating hospitals were required to have lower gastro-
intestinal endoscopy and pathology reports recorded elec-
tronically for at least 6 years prior to study start (2006). We 
searched endoscopy databases for patients who had undergone 
colonic examination before 31 December 2010, and searched 
pathology databases for reports of colorectal lesions. Endoscopy 
and pathology reports were pseudonymised and entered into a 
database (Oracle Corporation, Redwood City, California, USA). 
Summary values for size, histology and location were assigned to 
lesions seen at multiple examinations.16
After identifying patients with colonic examinations before 
31 December 2010, we looked back in these patients’ records 
to identify the first occurrence of an adenoma, defining this as 
baseline. Multiple examinations were sometimes required at 
baseline to fully examine the colon and remove detected lesions, 
which we grouped and defined as the baseline visit. Baseline 
visits sometimes spanned days or months. Subsequent colonic 
examinations were grouped into surveillance visits, using rules 
described elsewhere.16
We excluded patients without a colonoscopy or adenoma at 
baseline. We also excluded patients with CRC; a prior bowel 
resection; inflammatory bowel disease; polyposis, juvenile 
polyps, or hamartomatous polyps; Lynch syndrome or family 
history of familial adenomatous polyposis; colorectal carci-
noma in situ reported more than 3 years before baseline; missing 
examination dates; or missing information needed for risk 
categorisation.
Following the 2002 UK guidelines,3 we classed patients 
into low- risk (1-2 adenomas <10 mm); intermediate- risk (3-4 
adenomas <10 mm, or 1-2 adenomas with at least 1 ≥10 mm); 
and high- risk groups (5 or more adenomas <10 mm, or 3 or 
more adenomas with at least 1 ≥10 mm).
We obtained data on cancers and deaths from National Health 
Service (NHS) Digital, NHS Central Register, and National 
Services Scotland through 2016 and entered these into the study 
database. We compared the cancer data with the hospital data 
and resolved data duplication and inconsistency issues.
The primary outcome was incident adenocarcinoma of the 
colorectum, including cancers with unspecified morphology 
but assumed to be adenocarcinomas (those located between the 
rectum and caecum). In situ cancers and cancers with unspeci-
fied morphology but assumed to be squamous cell carcinomas 
(those located around the anus) were not included as CRCs.
In line with previous methodology,13 16 we excluded CRCs 
that we assumed had arisen from incompletely resected baseline 
lesions because we thought their inclusion could lead to biased 
estimates of risk and inappropriate surveillance recommenda-
tions. Namely, we excluded CRCs found in the same/adjacent 
colonic segment to a baseline adenoma ≥15 mm that was seen 
at least twice within 5 years preceding cancer diagnosis. In sensi-
tivity analyses, we additionally excluded CRCs that satisfied only 
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some of these criteria, but that we deemed likely to have arisen 
from incompletely resected lesions.
Statistical analysis
Sample size calculations were based on obtaining estimates of 
CRC incidence with a coefficient of variation of ~30%. Assuming 
an incidence rate of two CRCs per 1000 person- years,17–19 nine 
CRCs and 4500 person- years in any risk subgroup would give 
a coefficient of variation of 33%. Thus, assuming the smallest 
subgroup would be 15% the size of the whole risk group, 60 
CRCs were required in each risk group.
We compared baseline characteristics among patients with 
and without surveillance using χ² tests, including sex, age, 
adenoma number, size, histology, and dysplasia, presence of 
proximal polyps, colonoscopy completeness, bowel preparation 
quality, year of baseline visit, length of baseline visit (in days or 
months), family history of cancer/CRC, number of hyperplastic 
polyps and presence of hyperplastic polyps ≥10 mm. Colonos-
copy completeness and bowel preparation quality were defined 
by the most complete colonoscopy and best preparation during 
baseline.
We estimated CRC incidence after baseline in each risk group. 
Time- at- risk started from the last examination at baseline. Time- 
to- event data were censored at first CRC diagnosis, death, 
emigration or date of complete ascertainment of cases in cancer 
registries.
We examined effects of surveillance and baseline character-
istics on CRC incidence. Exposure to successive surveillance 
visits started at the last examination in each visit. When CRC 
was diagnosed at a surveillance visit, we did not include the 
visit as surveillance as it offered no protection against CRC. We 
used univariable Cox proportional- hazards models to calculate 
hazard ratios (HRs) and 95% confidence intervals (CIs). Multi-
variable Cox regression was used to identify independent CRC 
risk factors, using backward stepwise selection based on likeli-
hood ratio tests to retain variables with p values <0.05. Number 
of surveillance visits was included as a time- varying covariate. 
Interactions between number of surveillance visits and age or sex 
were assessed by including interaction parameters.
We performed Kaplan- Meier analyses to show time to cancer 
diagnosis and estimate cumulative CRC incidence with 95% 
CIs at 3 years, 5 years and 10 years. Cumulative incidence 
curves were compared using the log- rank test. We calculated 
standardised incidence ratios (SIRs) as the ratio of observed to 
expected CRC cases, with exact Poisson 95% CIs. Expected 
cases were calculated by multiplying sex- specific and 5- year age- 
group- specific person- years by the corresponding incidence in 
the general population of England in 2007.20 We divided each 
patient’s follow- up time into distinct periods; in the absence of 
surveillance, censoring at first surveillance; after first surveil-
lance, censoring at second surveillance; and after second surveil-
lance to final censoring.
Using baseline risk factors, we stratified each risk group into 
lower- risk and higher- risk subgroups. Age was not included in 
the stratification criteria because older age is associated with 
worse colonoscopy quality and higher risks of complications;21 
nor was year or length of baseline visit which do not help define 
clinically relevant subgroups.
In our previous study of intermediate- risk patients, incomplete 
colonoscopies, colonoscopies of unknown completeness, poor 
bowel preparation, adenomas ≥20 mm, adenomas with high- 
grade dysplasia and proximal polyps were CRC risk factors.13 16 
In the present study, we used these factors to define higher- risk 
in a sensitivity analysis of the risk stratification criteria for 
intermediate- risk patients. Further sensitivity analyses excluded 
patients without a complete baseline colonoscopy.
Analyses were conducted in Stata/IC V.13.1 (StataCorp LP, 
2013; Stata Statistical Software: Release 13; College Station, 
Texas, USA). The study is registered (ISRCTN15213649). The 
protocol is available online.22
Patient and public involvement
Our patient and public representatives reviewed the study 
proposal and results and have helped to develop plans for wider 
dissemination of the results.
reSulTS
There were 33 011 eligible patients in the updated cohort. Of 
these, we excluded 2859 with no baseline colonoscopy; 125 with 
CRC at baseline or a condition associated with increased CRC 
risk; 15 whose baseline occurred after 2010; 12 with colorectal 
carcinoma in situ more than 3 years before baseline; 2 with 
missing examination dates; 2 without adenomas; 980 whose risk 
could not be classified; and 44 who were lost to follow- up. Of 
the remaining 28 972, 14 401 (50%) were classed as low- risk, 
11 852 (41%) as intermediate- risk and 2719 (9%) as high- risk 
(figure 1).
Patients attending surveillance were younger than non- 
attenders and generally more likely to have had more adenomas, 
an adenoma with tubulovillous histology or high- grade dysplasia, 
hyperplastic polyps or missing data at baseline. A greater propor-
tion of attenders than non- attenders had a baseline visit before 
2005, a baseline visit spanning more than 1 day and a family 
history of cancer/CRC. Non- attenders were more likely to have 
had an incomplete colonoscopy or poor bowel preparation. 
Among intermediate- risk patients, attenders were more likely 
to be male and have had an adenoma ≥20 mm or hyperplastic 
polyp ≥10 mm (online supplementary table 1).
The median age of low- risk patients was 64 years (IQR 55 to 
72), 44% were women and 50% attended surveillance (table 1). 
The median time to first surveillance was 3.2 years (IQR 2.2 
to 5.0). During a median follow- up of 9.6 years (IQR 7.2 to 
12.4), 195 CRCs were diagnosed, giving an incidence rate of 
140 per 100 000 person- years (table 1). Number of surveillance 
visits, age, adenoma histology, proximal polyps and colonoscopy 
completeness were independently associated with CRC inci-
dence. Adjusting for these factors, a single surveillance visit was 
associated with a 44% reduction in CRC incidence compared 
with no surveillance. Incidence was even lower with two surveil-
lance visits (table 1).
The median age of intermediate- risk patients was 66 years 
(IQR 58 to 74), 44% were women and 60% attended surveil-
lance (table 2). The median time to first surveillance was 3.0 
years (IQR 1.4 to 3.5). During a median follow- up of 9.1 years 
(IQR 6.6 to 12.4), 246 CRCs were diagnosed, giving an inci-
dence rate of 221 per 100 000 person- years (table 2). Number 
of surveillance visits, age, adenoma dysplasia, proximal polyps, 
colonoscopy completeness, and year and length of baseline visit 
were independently associated with CRC incidence. Adenoma 
histology was not included in the final multivariable model 
because it was only associated with incidence when the unknown 
category was included. Adjusting for the other factors, a single 
surveillance visit was associated with a 41% reduction in CRC 
incidence compared with no surveillance. A similar reduction in 
incidence was seen with two surveillance visits (table 2).
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Figure 1 Study profile. 
*Not mutually exclusive. †Reasons for lost to follow- up: 19 patients had all examinations after emigrating; 22 patients were untraceable through 
national data sources and had no surveillance; and 3 patients had an unknown date of birth.
The median age of high- risk patients was 67 years (IQR 61 to 
74), 29% were women and 66% attended surveillance (table 3). 
The median time to first surveillance was 1.5 years (IQR 1.0 to 
3.0). During a median follow- up of 8.4 years (IQR 5.7 to 11.2), 84 
CRCs were diagnosed, giving an incidence rate of 366 per 100 000 
person- years (table 3). Number of surveillance visits, adenoma 
dysplasia and colonoscopy completeness were independently asso-
ciated with CRC incidence. Adjusting for these factors, a single 
surveillance visit was associated with a halving of CRC incidence 
compared with no surveillance. Attendance at subsequent visits 
was associated with further incidence reductions (table 3).
There were no significant interactions between number of 
surveillance visits and age or sex (all p values ≥0.05). Each risk 
group was then divided into lower- risk and higher- risk subgroups 
using the identified baseline risk factors.
low-risk group
The higher- risk subgroup of low- risk patients comprised those 
with incomplete colonoscopies, colonoscopies of unknown 
completeness, tubulovillous or villous adenomas, or proximal 
polyps at baseline (n=9166, 64%); lower- risk patients had none 
of these (n=5235, 36%) (table 4). Higher- risk patients were older, 
more likely to have had a baseline visit before 2005, and had more 
surveillance than lower- risk patients (online supplementary table 
2). Surveillance was associated with lower CRC incidence in the 
higher- risk but not the lower- risk subgroup; however, estimates 
in the lower- risk subgroup were imprecise owing to few CRCs 
(table 4).
Without surveillance, cumulative CRC incidence at 10 
years was 1.7% (95% CI 1.4 to 2.1) in the whole low- risk 
group, differing significantly between the lower- risk (1.2%, 
95% CI 0.8 to 1.7) and higher- risk subgroups (2.1%, 95% 
CI 1.7 to 2.6) (table 5; figure 2). Compared with the general 
population, CRC incidence was similar in the whole low- 
risk group (SIR 0.86, 95% CI 0.73 to 1.02) and higher- risk 
subgroup (SIR 1.07, 95% CI 0.88 to 1.28), but was lower 
in the lower- risk subgroup (SIR 0.51, 95% CI 0.35 to 0.73) 
(table 5). After first surveillance, cumulative CRC incidence 
was lower (table 5; figure 2) and incidence in both subgroups 
was below that in the general population (table 5).
Intermediate-risk group
The higher- risk subgroup of intermediate- risk patients comprised 
those with incomplete colonoscopies, colonoscopies of unknown 
completeness, adenomas with high- grade dysplasia or proximal 
polyps at baseline (n=7114, 60%); lower- risk patients had none 
of these (n=4738, 40%) (table 4). Higher- risk patients were 
older, more likely to have had a baseline visit before 2005, and 
had more surveillance than lower- risk patients (online supple-
mentary table 2). Surveillance was associated with reduced CRC 
incidence in the higher- risk but not the lower- risk subgroup, 
although estimates in the lower- risk subgroup were imprecise 
(table 4).
Without surveillance, cumulative CRC incidence 
at 10 years was 2.6% (95% CI 2.1 to 3.3) in the whole 
intermediate- risk group, differing significantly between the 
lower- risk (1.3%, 95% CI 0.8 to 2.1) and higher- risk (3.7%, 
95% CI 2.9 to 4.7) subgroups (table 5; figure 3). Compared 
with the general population, CRC incidence was similar in 
the whole intermediate- risk group (SIR 1.16, 95% CI 0.97 
to 1.37), lower in the lower- risk subgroup (SIR 0.70, 95% 
CI 0.48 to 0.99) and higher in the higher- risk subgroup (SIR 
1.46, 95% CI 1.19 to 1.78) (table 5).
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Table 1 Long- term colorectal cancer (CRC) incidence in the low- risk group by baseline characteristics and number of surveillance visits
n (%) Person- years CrC cases
Incidence per 100 000 
person- years (95% CI) univariable Hr (95% CI) P value Multivariable Hr (95% CI) P value
Total 14 401 (100) 138 903 195 140 (122 to 162) – – – –
Number of surveillance visits* – – – – – <0.0001 – <0.0001
  0 7207 (50.1) 84 591 143 169 (143 to 199) 1 – 1 –
  1 3959 (27.5) 34 507 41 119 (87 to 161) 0.55 (0.39 to 0.79) – 0.56 (0.39 to 0.80) –
  2 1943 (13.5) 12 986 8 62 (31 to 123) 0.26 (0.12 to 0.54) – 0.27 (0.13 to 0.56) –
  ≥3 1292 (9.0) 6818 3 44 (14 to 136) 0.17 (0.05 to 0.57) – 0.18 (0.05 to 0.58) –
Sex – – – – – 0.67 – 0.99
  Women 6382 (44.3) 63 337 92 145 (118 to 178) 1 – 1 –
  Men 8019 (55.7) 75 567 103 136 (112 to 165) 0.94 (0.71 to 1.25) – 1.00 (0.75 to 1.32) –
Age, years – – – – – <0.0001 – <0.0001
  <55 3569 (24.8) 40 422 21 52 (34 to 80) 1 – 1 –
  55–64 3991 (27.7) 42 121 46 109 (82 to 146) 2.12 (1.26 to 3.55) – 2.05 (1.22 to 3.44) –
  65–74 4258 (29.6) 38 799 76 196 (156 to 245) 3.87 (2.38 to 6.28) – 3.52 (2.17 to 5.73) –
  ≥75 2583 (17.9) 17 561 52 296 (226 to 389) 6.12 (3.67 to 10.20) – 5.02 (3.00 to 8.39) –
Number of adenomas – – – – – 0.30 – 0.69
  1 11 762 (81.7) 113 729 154 135 (116 to 159) 1 – 1 –
  2 2639 (18.3) 25 175 41 163 (120 to 221) 1.20 (0.85 to 1.70) – 1.07 (0.76 to 1.53) –
Adenoma histology† – – – – – 0.0093 – 0.0067
  Tubular 11 138 (77.3) 107 018 132 123 (104 to 146) 1 – 1 –
  Tubulovillous 2113 (14.7) 20 130 44 219 (163 to 294)
1.69 (1.21 to 2.37)
–
1.71 (1.21 to 2.40)
–
  Villous 190 (1.3) 1906 2 105 (26 to 420) – –
  Unknown 960 (6.7) 9849 17 173 (107 to 278) 1.39 (0.84 to 2.30) – 1.52 (0.92 to 2.52) –
Adenoma dysplasia† – – – – – 0.0543 – 0.0775
  Low- grade 13 242 (92.0) 125 812 171 136 (117 to 158) 1 – 1 –
  High- grade 357 (2.5) 3469 11 317 (176 to 573) 2.32 (1.26 to 4.28) – 2.20 (1.18 to 4.10) –
  Unknown 802 (5.6) 9623 13 135 (78 to 233) 0.99 (0.56 to 1.74) – 0.93 (0.52 to 1.66) –
Proximal polyps – – – – – 0.0046 – 0.002
  No 8133 (56.5) 80 118 93 116 (95 to 142) 1 – 1 –
  Yes 6268 (43.5) 58 785 102 174 (143 to 211) 1.50 (1.13 to 1.99) – 1.57 (1.18 to 2.10) –
Completeness of colonoscopy – – – – – 0.17 – 0.0274
  Complete 11 719 (81.4) 108 319 144 133 (113 to 157) 1 – 1 –
  Incomplete 1140 (7.9) 10 674 26 244 (166 to 358)
1.26 (0.91 to 1.74)
–
1.47 (1.05 to 2.04)
–
  Unknown 1542 (10.7) 19 910 25 126 (85 to 186) – –
Bowel preparation quality – – – – – 0.15 – 0.32
  Excellent or good 5145 (35.7) 52 129 84 161 (130 to 200) 1 – 1 –
  Satisfactory 2540 (17.6) 22 051 30 136 (95 to 195) 0.85 (0.56 to 1.29) – 0.81 (0.53 to 1.23) –
  Poor 968 (6.7) 7970 15 188 (113 to 312) 1.18 (0.68 to 2.04) – 1.09 (0.63 to 1.88) –
  Unknown 5748 (39.9) 56 754 66 116 (91 to 148) 0.72 (0.52 to 1.00) – 0.76 (0.55 to 1.05) –
Year of baseline visit – – – – – 0.71 – 0.45
  1984–1994 1640 (11.4) 23 185 32 138 (98 to 195) 1 – 1 –
  2000–2004 5168 (35.9) 56 134 86 153 (124 to 189) 1.06 (0.69 to 1.62) – 0.93 (0.60 to 1.43) –
  2005–2010 7593 (52.7) 59 585 77 129 (103 to 162) 0.92 (0.59 to 1.44) – 0.77 (0.48 to 1.23) –
Length of baseline visit – – – – – 0.74 – 0.64
  1 day 11 354 (78.8) 110 143 152 138 (118 to 162) 1 – 1 –
  2 days–3 months 1373 (9.5) 12 314 19 154 (98 to 242) 1.12 (0.70 to 1.81) – 1.13 (0.70 to 1.84) –
  3–6 months 950 (6.6) 9309 16 172 (105 to 281) 1.24 (0.74 to 2.07) – 1.39 (0.82 to 2.33) –
  ≥6 months 724 (5.0) 7137 8 112 (56 to 224) 0.81 (0.40 to 1.65) – 0.91 (0.45 to 1.87) –
The final multivariable model contained number of surveillance visits, age, adenoma histology, proximal polyps and completeness of colonoscopy. For these variables, the multivariable HRs were from the final multivariable model and the p values 
were for inclusion of the variable in the model, calculated with the likelihood ratio test. For the remaining variables, the multivariable HRs were for if the variable was added as an additional variable to the final multivariable model.
*The number of surveillance visits was included as a time- varying covariate; patients who attended any surveillance contributed person- years to more than one category of number of surveillance visits.
†Adenoma histology and dysplasia were defined according to the worst histology (greatest degree of villousness) and worst dysplasia (highest grade) seen at baseline, respectively.
After first surveillance, cumulative CRC incidence still differed 
between the risk subgroups (table 5; figure 3), although incidence 
in the higher- risk subgroup was now similar to that in the general 
population (SIR 1.00, 95% CI 0.73 to 1.33) and was lower in the 
lower- risk subgroup (SIR 0.59, 95% CI 0.34 to 0.96) (table 5).
When we additionally included poor bowel preparation and 
adenomas ≥20 mm in the classification of higher risk, the propor-
tion of patients classed as higher risk increased to 74%. Incidence 
rates and effects of surveillance on incidence remained similar 
(data not shown).
High-risk group
The higher- risk subgroup of high- risk patients included those 
with incomplete colonoscopies, colonoscopies of unknown 
completeness or adenomas with high- grade dysplasia at base-
line (n=902, 33%); lower- risk patients had none of these 
(n=1817, 67%) (table 4). The subgroups were similar regarding 
sex, age, year of baseline visit and number of surveillance visits 
(online supplementary table 2). Surveillance was associated with 
reduced CRC incidence in the higher- risk but not the lower- risk 
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Table 2 Long- term colorectal cancer (CRC) incidence in the intermediate- risk group by baseline characteristics and number of surveillance visits
n (%) Person- years
CrC 
cases
Incidence per 100 000 
person- years (95% CI)
univariable Hr 
(95% CI) P value
Multivariable Hr 
(95% CI) P value
Total 11 852 (100) 111 270 246 221 (195 to 251) – – – –
Number of surveillance visits* – – – – – 0.0004 – 0.0009
  0 4683 (39.5) 53 927 135 250 (211 to 296) 1 – 1 –
  1 3343 (28.2) 33 284 62 186 (145 to 239) 0.58 (0.42 to 0.79) – 0.59 (0.43 to 0.81) –
  2 2279 (19.2) 15 477 31 200 (141 to 285) 0.53 (0.35 to 0.81) – 0.56 (0.36 to 0.85) –
  ≥3 1547 (13.1) 8582 18 210 (132 to 333) 0.44 (0.26 to 0.77) – 0.45 (0.26 to 0.77) –
Sex – – – – – 0.28 – 0.0549
  Women 5271 (44.5) 51 049 105 206 (170 to 249) 1 – 1 –
  Men 6581 (55.5) 60 221 141 234 (199 to 276) 1.15 (0.89 to 1.48) – 1.28 (0.99 to 1.66) –
Age, years – – – – – <0.0001 – <0.0001
  <55 2097 (17.7) 24 995 28 112 (77 to 162) 1 – 1 –
  55–64 3158 (26.7) 33 530 52 155 (118 to 204) 1.44 (0.91 to 2.28) – 1.41 (0.89 to 2.24) –
  65–74 3915 (33.0) 35 391 98 277 (227 to 338) 2.74 (1.80 to 4.19) – 2.66 (1.74 to 4.06) –
  ≥75 2682 (22.6) 17 354 68 392 (309 to 497) 4.25 (2.71 to 6.65) – 3.64 (2.31 to 5.74) –
Number of adenomas – – – – – 0.37 – 0.20
  1 7793 (65.8) 74 791 168 225 (193 to 261) 1 – 1 –
  2 3053 (25.8) 27 502 64 233 (182 to 297) 1.06 (0.79 to 1.41) – 0.92 (0.68 to 1.25) –
  3 or 4 1006 (8.5) 8977 14 156 (92 to 263) 0.71 (0.41 to 1.23) – 0.61 (0.34 to 1.08) –
Adenoma size, mm† – – – – – 0.0866 – 0.18
  <10 1006 (8.5) 8977 14 156 (92 to 263) 1 – 1 –
  10–19 6802 (57.4) 64 716 134 207 (175 to 245) 1.30 (0.75 to 2.26) – 1.53 (0.87 to 2.70) –
  ≥20 4044 (34.1) 37 577 98 261 (214 to 318) 1.64 (0.94 to 2.88) – 1.69 (0.94 to 3.04) –
Adenoma histology‡ – – – – – <0.0001 – 0.0025
  Tubular 4694 (39.6) 44 369 71 160 (127 to 202) 1 – 1 –
  Tubulovillous 5537 (46.7) 51 211 114 223 (185 to 267) 1.40 (1.04 to 1.88) – 1.29 (0.95 to 1.75) –
  Villous 1134 (9.6) 10 108 31 307 (216 to 436) 1.93 (1.27 to 2.95) – 1.44 (0.93 to 2.24) –
  Unknown 487 (4.1) 5581 30 538 (376 to 769) 3.23 (2.10 to 4.98) – 2.76 (1.64 to 4.64) –
Adenoma dysplasia‡ – – – – – 0.0002 – 0.0038
  Low- grade 9399 (79.3) 87 581 166 190 (163 to 221) 1 – 1 –
  High- grade 1979 (16.7) 17 402 53 305 (233 to 399) 1.62 (1.19 to 2.21) – 1.47 (1.07 to 2.02) –
  Unknown 474 (4.0) 6287 27 429 (295 to 626) 2.11 (1.39 to 3.20) – 1.86 (1.21 to 2.86) –
Proximal polyps – – – – – 0.0284 – 0.0025
  No 8254 (69.6) 79 798 162 203 (174 to 237) 1 – 1 –
  Yes 3598 (30.4) 31 471 84 267 (216 to 331) 1.35 (1.04 to 1.76) – 1.54 (1.17 to 2.02) –
Completeness of colonoscopy – – – – – 0.0007 – 0.0022
  Complete 8967 (75.7) 80 572 150 186 (159 to 218) 1 1 –
  Incomplete 1321 (11.2) 11 545 49 424 (321 to 562)
1.58 (1.22 to 2.06)
–
1.55 (1.18 to 2.06)
–
  Unknown 1564 (13.2) 19 152 47 245 (184 to 327) – –
Bowel preparation quality – – – – – 0.13 – 0.14
  Excellent or good 3974 (33.5) 37 493 71 189 (150 to 239) 1 – 1 –
  Satisfactory 1903 (16.1) 15 451 36 233 (168 to 323) 1.28 (0.86 to 1.92) – 1.47 (0.98 to 2.22) –
  Poor 660 (5.6) 4840 17 351 (218 to 565) 1.92 (1.13 to 3.25) – 1.67 (0.98 to 2.85) –
  Unknown 5315 (44.8) 53 485 122 228 (191 to 272) 1.17 (0.88 to 1.57) – 1.13 (0.84 to 1.53) –
Year of baseline visit – – – – – 0.0044 – 0.0078
  1984–1999 1870 (15.8) 25 329 83 328 (264 to 406) 1 – 1 –
  2000–2004 4222 (35.6) 42 957 92 214 (175 to 263) 0.66 (0.48 to 0.90) – 0.63 (0.46 to 0.87) –
  2005–2010 5760 (48.6) 42 983 71 165 (131 to 208) 0.57 (0.40 to 0.80) – 0.59 (0.40 to 0.85) –
Length of baseline visit – – – – – 0.0181 – 0.0082
  1 day 6697 (56.5) 63 453 117 184 (154 to 221) 1 – 1 –
  2 days–3 months 2343 (19.8) 21 669 60 277 (215 to 357) 1.53 (1.12 to 2.08) – 1.65 (1.20 to 2.26) –
  3–6 months 1403 (11.8) 13 277 32 241 (170 to 341) 1.32 (0.89 to 1.95) – 1.34 (0.90 to 1.99) –
  ≥6 months 1409 (11.9) 12 871 37 287 (208 to 397) 1.57 (1.09 to 2.27) – 1.58 (1.08 to 2.30) –
The final multivariable model contained number of surveillance visits, age, adenoma dysplasia, proximal polyps, completeness of colonoscopy, year of baseline visit and length of baseline visit. 
For these variables, the multivariable HRs were from the final multivariable model and the p values were for inclusion of the variable in the model, calculated with the likelihood ratio test. For the 
remaining variables, the multivariable HRs were for if the variable was added as an additional variable to the final multivariable model.
*The number of surveillance visits was included as a time- varying covariate; patients who attended any surveillance contributed person- years to more than one category of number of surveillance 
visits.
†Adenoma size was defined according to the largest adenoma seen at baseline.
‡Adenoma histology and dysplasia were defined according to the worst histology (greatest degree of villousness) and worst dysplasia (highest grade) seen at baseline, respectively.
 o
n
 February 3, 2020 at Newcastle University. Protected by copyright.
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2019-320036 on 17 January 2020. Downloaded from 
7cross aJ, et al. Gut 2020;0:1–14. doi:10.1136/gutjnl-2019-320036
GI cancer
Table 3 Long- term colorectal cancer (CRC) incidence in the high- risk group by baseline characteristics and number of surveillance visits
n (%) Person- years
CrC 
cases
Incidence per 100 000 
person- years (95% CI) univariable Hr (95% CI) P value
Multivariable Hr 
(95% CI) P value
Total 2719 (100) 22 961 84 366 (295 to 453) – – – –
Number of surveillance visits* – – – – – 0.0019 – 0.0009
  0 911 (33.5) 9243 44 476 (354 to 640) 1 – 1 –
  1 695 (25.6) 7144 24 336 (225 to 501) 0.51 (0.30 to 0.85) – 0.49 (0.29 to 0.82) –
  2 593 (21.8) 4018 10 249 (134 to 463) 0.32 (0.16 to 0.67) – 0.30 (0.15 to 0.62) –
  ≥3 520 (19.1) 2555 6 235 (105 to 523) 0.31 (0.12 to 0.78) – 0.29 (0.11 to 0.73) –
Sex – – – – – 0.32 – 0.56
  Women 799 (29.4) 6997 30 429 (300 to 613) 1 – 1 –
  Men 1920 (70.6) 15 963 54 338 (259 to 442) 0.79 (0.51 to 1.24) – 0.87 (0.56 to 1.37) –
Age, years – – – – – 0.0118 – 0.0828
  <55 283 (10.4) 3191 6 188 (84 to 418) 1 – 1 –
  55–64 750 (27.6) 7082 20 282 (182 to 438) 1.53 (0.61 to 3.81) – 1.68 (0.67 to 4.19) –
  65–74 1065 (39.2) 8735 34 389 (278 to 545) 2.13 (0.89 to 5.09) – 2.17 (0.91 to 5.19) –
  ≥75 621 (22.8) 3953 24 607 (407 to 906) 3.42 (1.39 to 8.42) – 2.79 (1.13 to 6.89) –
Number of adenomas – – – – – 0.49 – 0.38
  3 1227 (45.1) 10 577 38 359 (261 to 494) 1 – 1 –
  4 557 (20.5) 4704 13 276 (160 to 476) 0.77 (0.41 to 1.45) – 0.81 (0.43 to 1.53) –
  5 454 (16.7) 3697 18 487 (307 to 773) 1.35 (0.77 to 2.36) – 1.45 (0.83 to 2.54) –
  ≥6 481 (17.7) 3983 15 377 (227 to 625) 1.05 (0.58 to 1.92) – 1.24 (0.68 to 2.27) –
Adenoma size, mm† – – – – – 0.30 – 0.69
  <10 264 (9.7) 2374 6 253 (114 to 562) 1 – 1 –
  10–19 1344 (49.4) 11 361 36 317 (229 to 439) 1.25 (0.53 to 2.97) – 1.08 (0.45 to 2.57) –
  ≥20 1084 (39.9) 8951 41 458 (337 to 622) 1.82 (0.77 to 4.28) – 1.41 (0.58 to 3.39) –
  Unknown 27 (1.0) 275 1 364 (51 to 2585) 1.41 (0.17 to 11.76) – 1.22 (0.14 to 10.31) –
Adenoma histology‡ – – – – – 0.19 – 0.48
  Tubular 1038 (38.2) 8994 31 345 (242 to 490) 1 – 1 –
  Tubulovillous 1293 (47.6) 10 701 36 336 (243 to 466) 0.99 (0.61 to 1.59) – 0.89 (0.55 to 1.45) –
  Villous 328 (12.1) 2648 16 604 (370 to 986) 1.77 (0.97 to 3.23) – 1.40 (0.75 to 2.61) –
  Unknown 60 (2.2) 619 1 162 (23 to 1147) 0.47 (0.06 to 3.41) – 0.54 (0.07 to 4.09) –
Adenoma dysplasia‡ – – – – – 0.0027 – 0.0009
  Low- grade 2035 (74.8) 17 109 51 298 (227 to 392) 1 – 1 –
  High- grade 616 (22.7) 5080 32 630 (445 to 891) 2.12 (1.36 to 3.30) – 2.23 (1.43 to 3.47) –
  Unknown 68 (2.5) 772 1 130 (18 to 919) 0.44 (0.06 to 3.21) – 0.35 (0.05 to 2.57) –
Proximal polyps – – – – – 0.96 – 0.47
  No 663 (24.4) 5934 22 371 (244 to 563) 1 – 1 –
  Yes 2056 (75.6) 17 027 62 364 (284 to 467) 0.99 (0.61 to 1.61) – 1.21 (0.73 to 2.00) –
Completeness of colonoscopy – – – – – 0.0612 – 0.0438
  Complete 2354 (86.6) 19 266 64 332 (260 to 424) 1 – 1 –
  Incomplete 123 (4.5) 1009 7 694 (331 to 1456)
1.66 (1.00 to 2.76)
–
1.73 (1.04 to 2.89)
–
  Unknown 242 (8.9) 2686 13 484 (281 to 833) – –
Bowel preparation quality – – – – – 0.89 – 0.89
  Excellent or good 1119 (41.2) 9788 35 358 (257 to 498) 1 – 1 –
  Satisfactory 411 (15.1) 3106 12 386 (219 to 680) 1.08 (0.56 to 2.08) – 1.03 (0.53 to 1.99) –
  Poor 143 (5.3) 980 5 510 (212 to 1226) 1.46 (0.57 to 3.72) – 1.42 (0.55 to 3.64) –
  Unknown 1046 (38.5) 9086 32 352 (249 to 498) 0.99 (0.61 to 1.59) – 0.95 (0.59 to 1.53) –
Year of baseline visit – – – – – 0.41 – 0.36
  1984–1999 329 (12.1) 3948 10 253 (136 to 471) 1 – 1 –
  2000–2004 874 (32.1) 8250 34 412 (294 to 577) 1.62 (0.78 to 3.38) – 1.65 (0.78 to 3.47) –
  2005–2010 1516 (55.8) 10 762 40 372 (273 to 507) 1.48 (0.70 to 3.13) – 1.65 (0.75 to 3.62) –
Length of baseline visit – – – – – 0.60 – 0.88
  1 day 1184 (43.6) 10 106 33 327 (232 to 459) 1 – 1 –
  2 days–3 months 562 (20.7) 4556 18 395 (249 to 627) 1.20 (0.68 to 2.14) – 1.02 (0.57 to 1.82) –
  3–6 months 442 (16.3) 3738 12 321 (182 to 565) 0.98 (0.51 to 1.89) – 0.89 (0.46 to 1.74) –
  ≥6 months 531 (19.5) 4561 21 460 (300 to 706) 1.42 (0.82 to 2.45) – 1.19 (0.67 to 2.10) –
The final multivariable model contained number of surveillance visits, completeness of colonoscopy and adenoma dysplasia. For these variables, the multivariable HRs were from the final multivariable model 
and the p values were for inclusion of the variable in the model, calculated with the likelihood ratio test. For the remaining variables, the multivariable HRs were for if the variable was added as an additional 
variable to the final multivariable model.
*The number of surveillance visits was included as a time- varying covariate; patients who attended any surveillance contributed person- years to more than one category of number of surveillance visits.
†Adenoma size was defined according to the largest adenoma seen at baseline.
‡Adenoma histology and dysplasia were defined according to the worst histology (greatest degree of villousness) and worst dysplasia (highest grade) seen at baseline, respectively.
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Table 4 Incidence of colorectal cancer (CRC) and unadjusted effect of surveillance on CRC incidence by number of surveillance visits
n (%) Person- years CrC cases
Incidence per 100 000 person- 
years (95% CI)
effect of surveillance*
univariable Hr (95% CI) P value
low- risk group
  Whole risk group – – – – – <0.0001
   0 visits 7207 (50.1) 84 591 143 169 (143 to 199) 1 –
   1 visit 3959 (27.5) 34 507 41 119 (87 to 161) 0.55 (0.39 to 0.79) –
   ≥2 visits 3235 (22.5) 19 805 11 56 (31 to 100) 0.23 (0.12 to 0.44) –
   Total 14 401 (100) 138 903 195 140 (122 to 162) – –
  Lower- risk subgroup† – – – – – 0.15
   0 visits 2804 (53.6) 32 903 31 94 (66 to 134) 1 –
   1 visit 1432 (27.4) 11 410 8 70 (35 to 140) 0.54 (0.25 to 1.20) –
   ≥2 visits 999 (19.1) 5472 3 55 (18 to 170) 0.42 (0.12 to 1.48) –
   Total 5235 (36.4) 49 785 42 84 (62 to 114) – –
  Higher- risk subgroup† – – – – – <0.0001
   0 visits 4403 (48.0) 51 688 112 217 (180 to 261) 1 –
   1 visit 2527 (27.6) 23 097 33 143 (102 to 201) 0.52 (0.35 to 0.78) –
   ≥2 visits 2236 (24.4) 14 332 8 56 (28 to 112) 0.18 (0.08 to 0.37) –
   Total 9166 (63.6) 89 118 153 172 (147 to 201) – –
Intermediate- risk group
  Whole risk group – – – – – 0.0001
   0 visits 4683 (39.5) 53 927 135 250 (211 to 296) 1 –
   1 visit 3343 (28.2) 33 284 62 186 (145 to 239) 0.58 (0.42 to 0.79) –
   ≥2 visits 3826 (32.3) 24 059 49 204 (154 to 269) 0.50 (0.34 to 0.73) –
   Total 11 852 (100) 111 270 246 221 (195 to 251) – –
  Lower- risk subgroup‡ – – – – – 0.30
   0 visits 1932 (40.8) 23 237 33 142 (101 to 200) 1 –
   1 visit 1387 (29.3) 13 151 16 122 (75 to 199) 0.66 (0.35 to 1.23) –
   ≥2 visits 1419 (30.0) 8082 13 161 (93 to 277) 0.63 (0.31 to 1.29) –
   Total 4738 (40.0) 44 470 62 139 (109 to 179) – –
  Higher- risk subgroup‡ – – – – – 0.0001
   0 visits 2751 (38.7) 30 690 102 332 (274 to 404) 1 –
   1 visit 1956 (27.5) 20 133 46 228 (171 to 305) 0.53 (0.37 to 0.76) –
   ≥2 visits 2407 (33.8) 15 977 36 225 (163 to 312) 0.42 (0.27 to 0.65) –
   Total 7114 (60.0) 66 800 184 275 (238 to 318) – –
High- risk group
  Whole risk group – – – – – 0.0006
   0 visits 911 (33.5) 9243 44 476 (354 to 640) 1 –
   1 visit 695 (25.6) 7144 24 336 (225 to 501) 0.51 (0.30 to 0.85) –
   ≥2 visits 1113 (40.9) 6574 16 243 (149 to 397) 0.32 (0.17 to 0.60) –
   Total 2719 (100) 22 961 84 366 (295 to 453) – –
  Lower- risk subgroup§ – – – – – 0.26
   0 visits 606 (33.4) 6226 17 273 (170 to 439) 1 –
   1 visit 474 (26.1) 4766 12 252 (143 to 443) 0.66 (0.31 to 1.41) –
   ≥2 visits 737 (40.6) 4039 9 223 (116 to 428) 0.49 (0.20 to 1.18) –
   Total 1817 (66.8) 15 032 38 253 (184 to 347) – –
  Higher- risk subgroup§ – – – – – 0.0006
   0 visits 305 (33.8) 3017 27 895 (614 to 1305) 1 –
   1 visit 221 (24.5) 2378 12 505 (287 to 889) 0.41 (0.20 to 0.82) –
   ≥2 visits 376 (41.7) 2535 7 276 (132 to 579) 0.21 (0.08 to 0.51) –
   Total 902 (33.2) 7929 46 580 (435 to 775) – –
P values calculated with the likelihood ratio test.
*The number of surveillance visits was included as a time- varying covariate; patients who attended any surveillance contributed person- years to more than one category of 
number of surveillance visits.
†The higher- risk subgroup included patients with an incomplete colonoscopy or colonoscopy of unknown completeness, a tubulovillous or villous adenoma, or proximal polyps at 
baseline; the lower- risk subgroup included patients with none of these factors.
‡The higher- risk subgroup included patients with an incomplete colonoscopy or colonoscopy of unknown completeness, an adenoma with high- grade dysplasia or proximal 
polyps at baseline; the lower- risk subgroup included patients with none of these factors.
§The higher- risk subgroup included patients with an incomplete colonoscopy or colonoscopy of unknown completeness or an adenoma with high- grade dysplasia at baseline; 
the lower- risk subgroup included patients with none of these factors.
 o
n
 February 3, 2020 at Newcastle University. Protected by copyright.
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2019-320036 on 17 January 2020. Downloaded from 
9cross aJ, et al. Gut 2020;0:1–14. doi:10.1136/gutjnl-2019-320036
GI cancer
Ta
bl
e 
5 
Cu
m
ul
at
iv
e 
co
lo
re
ct
al
 c
an
ce
r (
CR
C)
 in
ci
de
nc
e 
an
d 
ag
e-
 st
an
da
rd
is
ed
 a
nd
 s
ex
- s
ta
nd
ar
di
se
d 
in
ci
de
nc
e 
ra
tio
s
n 
(%
)
Pe
rs
on
- y
ea
rs
Cr
C 
ca
se
s
In
ci
de
nc
e 
pe
r 
10
0 
00
0 
pe
rs
on
- y
ea
rs
 (9
5%
 C
I)
Fo
llo
w
- u
p
P 
va
lu
e
St
an
da
rd
is
at
io
n
3 
ye
ar
s
5 
ye
ar
s
10
 y
ea
rs
Cr
C 
ca
se
s
Cu
m
ul
at
iv
e 
in
ci
de
nc
e 
(9
5%
 C
I)*
Cr
C 
ca
se
s
Cu
m
ul
at
iv
e 
in
ci
de
nc
e 
(9
5%
 C
I)*
Cr
C 
ca
se
s
Cu
m
ul
at
iv
e 
in
ci
de
nc
e 
(9
5%
 C
I)*
ex
pe
ct
ed
 
Cr
Cs
†
SI
r 
(9
5%
 C
I)
lo
w
- r
is
k 
gr
ou
p
–
–
–
–
–
–
–
–
–
–
–
–
–
 
 Af
te
r b
as
el
in
e 
(n
o 
su
rv
ei
lla
nc
e,
 
ce
ns
or
ed
 a
t fi
rs
t s
ur
ve
ill
an
ce
)
–
–
–
–
–
–
–
–
–
–
<
0.
00
01
–
–
 
  
 W
ho
le
 ri
sk
 g
ro
up
14
 4
01
 (1
00
)
84
 5
91
14
3
16
9 
(1
43
 to
 1
99
)
45
0.
4%
 (0
.3
 to
 0
.5
)
77
0.
7%
 (0
.6
 to
 0
.9
)
12
4
1.
7%
 (1
.4
 to
 2
.1
)
–
16
5
0.
86
 (0
.7
3 
to
 1
.0
2)
 
  
 Lo
w
er
- r
is
k 
su
bg
ro
up
‡
52
35
 (3
6)
32
 9
03
31
94
 (6
6 
to
 1
34
)
6
0.
1%
 (0
.1
 to
 0
.3
)
11
0.
3%
 (0
.2
 to
 0
.5
)
29
1.
2%
 (0
.8
 to
 1
.7
)
–
60
0.
51
 (0
.3
5 
to
 0
.7
3)
 
  
 Hi
gh
er
- r
is
k 
su
bg
ro
up
‡
91
66
 (6
4)
51
 6
88
11
2
21
7 
(1
80
 to
 2
61
)
39
0.
5%
 (0
.4
 to
 0
.7
)
66
1.
0%
 (0
.8
 to
 1
.3
)
95
2.
1%
 (1
.7
 to
 2
.6
)
–
10
5
1.
07
 (0
.8
8 
to
 1
.2
8)
 
 Af
te
r fi
rs
t s
ur
ve
ill
an
ce
 (s
in
gl
e 
su
rv
ei
lla
nc
e 
vi
si
t, 
ce
ns
or
ed
 a
t 
se
co
nd
 s
ur
ve
ill
an
ce
)
–
–
–
–
–
–
–
–
–
–
0.
06
91
–
–
 
  
 W
ho
le
 ri
sk
 g
ro
up
71
94
 (1
00
)
34
 5
07
41
11
9 
(8
7 
to
 1
61
)
14
0.
2%
 (0
.1
 to
 0
.4
)
27
0.
6%
 (0
.4
 to
 0
.8
)
40
1.
5%
 (1
.0
 to
 2
.3
)
–
69
0.
60
 (0
.4
3 
to
 0
.8
1)
 
  
 Lo
w
er
- r
is
k 
su
bg
ro
up
‡
24
31
 (3
4)
11
 4
10
8
70
 (3
5 
to
 1
40
)
5
0.
2%
 (0
.1
 to
 0
.6
)
7
0.
4%
 (0
.2
 to
 0
.8
)
8
0.
6%
 (0
.2
 to
 1
.4
)
–
21
0.
38
 (0
.1
6 
to
 0
.7
4)
 
  
 Hi
gh
er
- r
is
k 
su
bg
ro
up
‡
47
63
 (6
6)
23
 0
97
33
14
3 
(1
02
 to
 2
01
)
9
0.
2%
 (0
.1
 to
 0
.4
)
20
0.
7%
 (0
.4
 to
 1
.0
)
32
2.
0%
 (1
.3
 to
 3
.0
)
–
47
0.
70
 (0
.4
8 
to
 0
.9
8)
 
 Af
te
r s
ec
on
d 
su
rv
ei
lla
nc
e 
(tw
o 
or
 
m
or
e 
su
rv
ei
lla
nc
e 
vi
si
ts
, c
en
so
re
d 
at
 e
nd
 o
f f
ol
lo
w
- u
p)
–
–
–
–
–
–
–
–
–
–
0.
90
–
–
 
  
 W
ho
le
 ri
sk
 g
ro
up
32
35
 (1
00
)
19
 8
05
11
56
 (3
1 
to
 1
00
)
1
0.
04
%
 (0
.0
1 
to
 0
.3
)
4
0.
2%
 (0
.1
 to
 0
.5
)
8
0.
6%
 (0
.3
 to
 1
.3
)
–
42
0.
26
 (0
.1
3 
to
 0
.4
7)
 
  
 Lo
w
er
- r
is
k 
su
bg
ro
up
‡
99
9 
(3
1)
54
72
3
55
 (1
8 
to
 1
70
)
0
–
0
–
2
0.
7%
 (0
.2
 to
 3
.0
)
–
10
0.
29
 (0
.0
6 
to
 0
.8
4)
 
  
 Hi
gh
er
- r
is
k 
su
bg
ro
up
‡
22
36
 (6
9)
14
 3
32
8
56
 (2
8 
to
 1
12
)
1
0.
1%
 (0
.0
1 
to
 0
.4
)
4
0.
3%
 (0
.1
 to
 0
.7
)
6
0.
6%
 (0
.2
 to
 1
.4
)
–
32
0.
25
 (0
.1
1 
to
 0
.5
0)
In
te
rm
ed
ia
te
- r
is
k 
gr
ou
p
–
–
–
–
–
–
–
–
–
–
–
–
–
 
 Af
te
r b
as
el
in
e 
(n
o 
su
rv
ei
lla
nc
e,
 
ce
ns
or
ed
 a
t fi
rs
t s
ur
ve
ill
an
ce
)
–
–
–
–
–
–
–
–
–
–
<
0.
00
01
–
–
 
  
 W
ho
le
 ri
sk
 g
ro
up
11
 8
52
 (1
00
)
53
 9
27
13
5
25
0 
(2
11
 to
 2
96
)
57
0.
6%
 (0
.5
 to
 0
.8
)
88
1.
3%
 (1
.0
 to
 1
.6
)
12
1
2.
6%
 (2
.1
 to
 3
.3
)
–
11
7
1.
16
 (0
.9
7 
to
 1
.3
7)
 
  
 Lo
w
er
- r
is
k 
su
bg
ro
up
§
47
38
 (4
0)
23
 2
37
33
14
2 
(1
01
 to
 2
00
)
13
0.
4%
 (0
.2
 to
 0
.6
)
20
0.
7%
 (0
.4
 to
 1
.1
)
27
1.
3%
 (0
.8
 to
 2
.1
)
–
47
0.
70
 (0
.4
8 
to
 0
.9
9)
 
  
 Hi
gh
er
- r
is
k 
su
bg
ro
up
§
71
14
 (6
0)
30
 6
90
10
2
33
2 
(2
74
 to
 4
04
)
44
0.
8%
 (0
.6
 to
 1
.1
)
68
1.
7%
 (1
.3
 to
 2
.2
)
94
3.
7%
 (2
.9
 to
 4
.7
)
–
70
1.
46
 (1
.1
9 
to
 1
.7
8)
 
 Af
te
r fi
rs
t s
ur
ve
ill
an
ce
 (s
in
gl
e 
su
rv
ei
lla
nc
e 
vi
si
t,  
ce
ns
or
ed
 a
t 
se
co
nd
 s
ur
ve
ill
an
ce
)
–
–
–
–
–
–
–
–
–
–
0.
02
92
–
–
 
  
 W
ho
le
 ri
sk
 g
ro
up
71
69
 (1
00
)
33
 2
84
62
18
6 
(1
45
 to
 2
39
)
17
0.
3%
 (0
.2
 to
 0
.5
)
34
0.
8%
 (0
.6
 to
 1
.2
)
57
2.
6%
 (1
.9
 to
 3
.6
)
–
73
0.
85
 (0
.6
5 
to
 1
.0
8)
 
  
 Lo
w
er
- r
is
k 
su
bg
ro
up
§
28
06
 (3
9)
13
 1
51
16
12
2 
(7
5 
to
 1
99
)
3
0.
1%
 (0
.0
4 
to
 0
.4
)
8
0.
5%
 (0
.2
 to
 1
.0
)
15
1.
9%
 (1
.0
 to
 3
.4
)
–
27
0.
59
 (0
.3
4 
to
 0
.9
6)
 
  
 Hi
gh
er
- r
is
k 
su
bg
ro
up
§
43
63
 (6
1)
20
 1
33
46
22
8 
(1
71
 to
 3
05
)
14
0.
4%
 (0
.2
 to
 0
.7
)
26
1.
0%
 (0
.7
 to
 1
.5
)
42
3.
1%
 (2
.2
 to
 4
.5
)
–
46
1.
00
 (0
.7
3 
to
 1
.3
3)
 
 Af
te
r s
ec
on
d 
su
rv
ei
lla
nc
e 
(tw
o 
or
 
m
or
e 
su
rv
ei
lla
nc
e 
vi
si
ts
, c
en
so
re
d 
at
 e
nd
 o
f f
ol
lo
w
- u
p)
–
–
–
–
–
–
–
–
–
–
0.
39
–
–
 
  
 W
ho
le
 ri
sk
 g
ro
up
38
26
 (1
00
)
24
 0
59
49
20
4 
(1
54
 to
 2
69
)
10
0.
3%
 (0
.2
 to
 0
.6
)
19
0.
7%
 (0
.4
 to
 1
.1
)
36
2.
0%
 (1
.4
 to
 2
.9
)
–
56
0.
87
 (0
.6
5 
to
 1
.1
6)
 
  
 Lo
w
er
- r
is
k 
su
bg
ro
up
§
14
19
 (3
7)
80
82
13
16
1 
(9
3 
to
 2
77
)
3
0.
3%
 (0
.1
 to
 0
.8
)
6
0.
6%
 (0
.3
 to
 1
.5
)
10
1.
7%
 (0
.8
 to
 3
.3
)
–
18
0.
72
 (0
.3
8 
to
 1
.2
2)
 
  
 Hi
gh
er
- r
is
k 
su
bg
ro
up
§
24
07
 (6
3)
15
 9
77
36
22
5 
(1
63
 to
 3
12
)
7
0.
3%
 (0
.2
 to
 0
.7
)
13
0.
7%
 (0
.4
 to
 1
.2
)
26
2.
2%
 (1
.4
 to
 3
.3
)
–
38
0.
95
 (0
.6
7 
to
 1
.3
1)
H
ig
h-
 ri
sk
 g
ro
up
–
–
–
–
–
–
–
–
–
–
–
–
–
 
 Af
te
r b
as
el
in
e 
(n
o 
su
rv
ei
lla
nc
e,
 
ce
ns
or
ed
 a
t fi
rs
t s
ur
ve
ill
an
ce
)
–
–
–
–
–
–
–
–
–
–
0.
00
01
–
–
 
  
 W
ho
le
 ri
sk
 g
ro
up
27
19
 (1
00
)
92
43
44
47
6 
(3
54
 to
 6
40
)
17
1.
0%
 (0
.6
 to
 1
.7
)
32
3.
1%
 (2
.1
 to
 4
.4
)
41
5.
7%
 (4
.0
 to
 8
.3
)
–
23
1.
91
 (1
.3
9 
to
 2
.5
6)
 
  
 Lo
w
er
- r
is
k 
su
bg
ro
up
¶
18
17
 (6
7)
62
26
17
27
3 
(1
70
 to
 4
39
)
7
0.
6%
 (0
.3
 to
 1
.4
)
13
1.
9%
 (1
.0
 to
 3
.4
)
17
3.
8%
 (2
.1
 to
 6
.8
)
–
15
1.
10
 (0
.6
4 
to
 1
.7
6)
 
  
 Hi
gh
er
- r
is
k 
su
bg
ro
up
¶
90
2 
(3
3)
30
17
27
89
5 
(6
14
 to
 1
30
5)
10
1.
9%
 (1
.0
 to
 3
.6
)
19
5.
6%
 (3
.5
 to
 9
.0
)
24
9.
9%
 (6
.2
 to
 1
5.
7)
–
8
3.
55
 (2
.3
4 
to
 5
.1
7)
Co
nt
in
ue
d
 o
n
 February 3, 2020 at Newcastle University. Protected by copyright.
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2019-320036 on 17 January 2020. Downloaded from 
10 cross aJ, et al. Gut 2020;0:1–14. doi:10.1136/gutjnl-2019-320036
GI cancer
n 
(%
)
Pe
rs
on
- y
ea
rs
Cr
C 
ca
se
s
In
ci
de
nc
e 
pe
r 
10
0 
00
0 
pe
rs
on
- y
ea
rs
 (9
5%
 C
I)
Fo
llo
w
- u
p
P 
va
lu
e
St
an
da
rd
is
at
io
n
3 
ye
ar
s
5 
ye
ar
s
10
 y
ea
rs
Cr
C 
ca
se
s
Cu
m
ul
at
iv
e 
in
ci
de
nc
e 
(9
5%
 C
I)*
Cr
C 
ca
se
s
Cu
m
ul
at
iv
e 
in
ci
de
nc
e 
(9
5%
 C
I)*
Cr
C 
ca
se
s
Cu
m
ul
at
iv
e 
in
ci
de
nc
e 
(9
5%
 C
I)*
ex
pe
ct
ed
 
Cr
Cs
†
SI
r 
(9
5%
 C
I)
 
 Af
te
r fi
rs
t s
ur
ve
ill
an
ce
 (s
in
gl
e 
su
rv
ei
lla
nc
e 
vi
si
t, 
ce
ns
or
ed
 a
t 
se
co
nd
 s
ur
ve
ill
an
ce
)
–
–
–
–
–
–
–
–
–
–
0.
08
64
–
–
 
  
 W
ho
le
 ri
sk
 g
ro
up
18
08
 (1
00
)
71
44
24
33
6 
(2
25
 to
 5
01
)
9
0.
6%
 (0
.3
 to
 1
.2
)
16
1.
8%
 (1
.1
 to
 3
.1
)
23
5.
6%
 (3
.1
 to
 9
.8
)
–
18
1.
34
 (0
.8
6 
to
 1
.9
9)
 
  
 Lo
w
er
- r
is
k 
su
bg
ro
up
¶
12
11
 (6
7)
47
66
12
25
2 
(1
43
 to
 4
43
)
5
0.
5%
 (0
.2
 to
 1
.3
)
8
1.
3%
 (0
.6
 to
 2
.9
)
11
4.
4%
 (1
.8
 to
 1
0.
6)
–
12
1.
01
 (0
.5
2 
to
 1
.7
6)
 
  
 Hi
gh
er
- r
is
k 
su
bg
ro
up
¶
59
7 
(3
3)
23
78
12
50
5 
(2
87
 to
 8
89
)
4
0.
9%
 (0
.3
 to
 2
.3
)
8
2.
9%
 (1
.4
 to
 6
.1
)
12
7.
8%
 (3
.8
 to
 1
5.
4)
–
6
1.
97
 (1
.0
2 
to
 3
.4
4)
 
 Af
te
r s
ec
on
d 
su
rv
ei
lla
nc
e 
(tw
o 
or
 
m
or
e 
su
rv
ei
lla
nc
e 
vi
si
ts
, c
en
so
re
d 
at
 e
nd
 o
f f
ol
lo
w
- u
p)
–
–
–
–
–
–
–
–
–
–
0.
74
–
–
 
  
 W
ho
le
 ri
sk
 g
ro
up
11
13
 (1
00
)
65
74
16
24
3 
(1
49
 to
 3
97
)
3
0.
3%
 (0
.1
 to
 1
.0
)
9
1.
2%
 (0
.6
 to
 2
.3
)
15
2.
6%
 (1
.5
 to
 4
.4
)
–
18
0.
91
 (0
.5
2 
to
 1
.4
7)
 
  
 Lo
w
er
- r
is
k 
su
bg
ro
up
¶
73
7 
(6
6)
40
39
9
22
3 
(1
16
 to
 4
28
)
1
0.
2%
 (0
.0
2 
to
 1
.2
)
6
1.
3%
 (0
.6
 to
 2
.8
)
9
2.
4%
 (1
.2
 to
 4
.7
)
–
11
0.
83
 (0
.3
8 
to
 1
.5
8)
 
  
 Hi
gh
er
- r
is
k 
su
bg
ro
up
¶
37
6 
(3
4)
25
35
7
27
6 
(1
32
 to
 5
79
)
2
0.
6%
 (0
.2
 to
 2
.4
)
3
1.
0%
 (0
.3
 to
 3
.1
)
6
2.
7%
 (1
.2
 to
 6
.2
)
–
7
1.
02
 (0
.4
1 
to
 2
.0
9)
P 
va
lu
es
 c
al
cu
la
te
d 
w
ith
 th
e 
lo
g-
 ra
nk
 te
st
 to
 c
om
pa
re
 in
ci
de
nc
e 
in
 th
e 
lo
w
er
- r
is
k 
an
d 
hi
gh
er
- r
is
k 
su
bg
ro
up
s 
of
 e
ac
h 
ris
k 
gr
ou
p.
*O
ne
 m
in
us
 th
e 
Ka
pl
an
- M
ei
er
 e
st
im
at
or
 o
f t
he
 s
ur
vi
va
l f
un
ct
io
n 
w
as
 u
se
d 
to
 e
st
im
at
e 
th
e 
cu
m
ul
at
iv
e 
in
ci
de
nc
e 
of
 c
ol
or
ec
ta
l c
an
ce
r.
†E
xp
ec
te
d 
nu
m
be
rs
 o
f c
ol
or
ec
ta
l c
an
ce
rs
 w
er
e 
ca
lc
ul
at
ed
 b
y 
m
ul
tip
ly
in
g 
th
e 
se
x 
an
d 
5-
 ye
ar
 a
ge
- g
ro
up
- s
pe
ci
fic
 o
bs
er
ve
d 
pe
rs
on
- y
ea
rs
 b
y 
th
e 
co
rr
es
po
nd
in
g 
in
ci
de
nc
e 
ra
te
s 
in
 th
e 
ge
ne
ra
l p
op
ul
at
io
n 
of
 E
ng
la
nd
 in
 2
00
7.
‡T
he
 h
ig
he
r- r
is
k 
su
bg
ro
up
 in
cl
ud
ed
 p
at
ie
nt
s 
w
ith
 a
n 
in
co
m
pl
et
e 
co
lo
no
sc
op
y 
or
 c
ol
on
os
co
py
 o
f u
nk
no
w
n 
co
m
pl
et
en
es
s, 
a 
tu
bu
lo
vi
llo
us
 o
r v
ill
ou
s 
ad
en
om
a,
 o
r p
ro
xi
m
al
 p
ol
yp
s 
at
 b
as
el
in
e;
 th
e 
lo
w
er
- r
is
k 
su
bg
ro
up
 in
cl
ud
ed
 p
at
ie
nt
s 
w
ith
 n
on
e 
of
 th
es
e 
fa
ct
or
s.
§T
he
 h
ig
he
r- r
is
k 
su
bg
ro
up
 in
cl
ud
ed
 p
at
ie
nt
s 
w
ith
 a
n 
in
co
m
pl
et
e 
co
lo
no
sc
op
y 
or
 c
ol
on
os
co
py
 o
f u
nk
no
w
n 
co
m
pl
et
en
es
s, 
an
 a
de
no
m
a 
w
ith
 h
ig
h-
 gr
ad
e 
dy
sp
la
si
a 
or
 p
ro
xi
m
al
 p
ol
yp
s 
at
 b
as
el
in
e;
 th
e 
lo
w
er
- r
is
k 
su
bg
ro
up
 in
cl
ud
ed
 p
at
ie
nt
s 
w
ith
 n
on
e 
of
 th
es
e 
fa
ct
or
s.
¶T
he
 h
ig
he
r- r
is
k 
su
bg
ro
up
 in
cl
ud
ed
 p
at
ie
nt
s 
w
ith
 a
n 
in
co
m
pl
et
e 
co
lo
no
sc
op
y 
or
 c
ol
on
os
co
py
 o
f u
nk
no
w
n 
co
m
pl
et
en
es
s 
or
 a
n 
ad
en
om
a 
w
ith
 h
ig
h-
 gr
ad
e 
dy
sp
la
si
a 
at
 b
as
el
in
e;
 th
e 
lo
w
er
- r
is
k 
su
bg
ro
up
 in
cl
ud
ed
 p
at
ie
nt
s 
w
ith
 n
on
e 
of
 th
es
e 
fa
ct
or
s.
SI
R,
 s
ta
nd
ar
di
se
d 
in
ci
de
nc
e 
ra
tio
.
Ta
bl
e 
5 
Co
nt
in
ue
d
subgroup, although estimates in the lower- risk subgroup were 
imprecise (table 4).
Without surveillance, cumulative CRC incidence at 10 years 
was 5.7% (95% CI 4.0 to 8.3) in the whole high- risk group, 
differing significantly between the lower- risk (3.8%, 95% CI 2.1 
to 6.8) and higher- risk subgroups (9.9%, 95% CI 6.2 to 15.7) 
(table 5; figure 4). Compared with the general population, CRC 
incidence was higher in the whole high- risk group (SIR 1.91, 
95% CI 1.39 to 2.56) and higher- risk subgroup (SIR 3.55, 95% 
CI 2.34 to 5.17), but not significantly different in the lower- risk 
subgroup (SIR 1.10, 95% CI 0.64 to 1.76) (table 5).
After first surveillance, cumulative CRC incidence at 10 years 
was 5.6% (95% CI 3.1 to 9.8) in the whole high- risk group, 4.4% 
(95% CI 1.8 to 10.6) in the lower- risk subgroup and 7.8% (95% 
CI 3.8 to 15.4) in the higher- risk subgroup (table 5; figure 4). 
Compared with the general population, CRC incidence was not 
significantly different in the whole high- risk group (SIR 1.34, 
95% CI 0.86 to 1.99) or lower- risk subgroup (SIR 1.01, 95% CI 
0.52 to 1.76), but remained higher in the higher- risk subgroup 
(SIR 1.97, 95% CI 1.02 to 3.44). After a second surveillance 
visit, CRC incidence was no longer higher in the higher- risk 
subgroup than in the general population (table 5).
In the main analysis, we excluded CRCs assumed to have arisen 
from incompletely resected baseline lesions; those found in the 
same/adjacent colonic segment to a baseline adenoma ≥15 mm 
that was seen at least twice within 5 years preceding cancer diag-
nosis (intermediate- risk group, n=38; high- risk group, n=12). 
In sensitivity analyses, we additionally excluded CRCs that satis-
fied only some of these criteria, but that we deemed likely to 
have arisen from incompletely resected lesions (low- risk group, 
n=6; intermediate- risk group, n=29; high- risk group, n=7). 
This negligibly affected the results (data not shown). Excluding 
patients without a complete baseline colonoscopy (low- risk 
group, n=2682; intermediate- risk group, n=2885; high- risk 
group, n=365) had little impact (online supplementary tables 
3–7), although high- grade dysplasia was no longer significant in 
intermediate- risk patients (online supplementary table 4).
DISCuSSIOn
This is the largest study examining long- term CRC incidence 
following adenoma removal and the effects of surveillance on 
CRC incidence. We obtained data from 17 hospitals on 28 972 
patients who underwent baseline colonoscopy and polypectomy 
and were followed for a median of 9.3 years. Stratifying the 
cohort into low- risk (50%), intermediate- risk (41%) and high- 
risk (9%) groups according to the 2002 UK surveillance guide-
lines,3 we identified heterogeneity in CRC incidence and in the 
effects of surveillance on CRC incidence among each risk group.
Our analyses showed that patients in the low- risk group 
were indeed at low risk of CRC. Even among the two- thirds 
of the group at higher CRC risk than the rest owing to an 
incomplete colonoscopy, colonoscopy of unknown complete-
ness, tubulovillous or villous adenoma, or proximal polyps 
at baseline, CRC incidence was similar to that in the general 
population, without any surveillance. Among the remaining 
one- third, CRC incidence without surveillance was lower than 
in the general population. In a resource- constrained setting, it 
is important to consider the opportunity costs of performing 
surveillance in a particular patient group; we think that 
patients remaining at increased CRC risk following a high- 
quality baseline colonoscopy, as compared with the general 
population, should be prioritised. Given this, and considering 
the risks of colonoscopy, we think that patients classified as 
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Figure 2 Cumulative colorectal cancer incidence after baseline in the low- risk group. 
Cumulative colorectal cancer incidence with no surveillance (censoring at first surveillance) for the whole low- risk group (A) and the lower- risk and 
higher- risk subgroups (B). Cumulative colorectal cancer incidence after a single surveillance visit (censoring at second surveillance) for the whole low- 
risk group (C) and the lower- risk and higher- risk subgroups (D). 95% CIs are shown for each curve. The higher- risk subgroup included patients with an 
incomplete colonoscopy or colonoscopy of unknown completeness, a tubulovillous or villous adenoma, or proximal polyps at baseline; the lower- risk 
subgroup included patients with none of these factors.
low- risk do not require surveillance and they could instead be 
managed by screening.
Our results corroborated our previous finding that surveil-
lance is warranted for most but probably not all intermediate- risk 
patients.13 Among intermediate- risk patients with incom-
plete colonoscopies, colonoscopies of unknown completeness, 
adenomas with high- grade dysplasia or proximal polyps at base-
line (60% of the risk group), CRC incidence without surveillance 
was higher than in the general population and a single surveil-
lance visit conferred substantial protection against CRC. Among 
patients without these characteristics, CRC incidence was lower 
than in the general population after baseline colonoscopy, indi-
cating that surveillance is not necessary.
Incidence of CRC was high in the high- risk group; without 
surveillance, rates were double that in the general population. 
Cumulative incidence at 10 years was 6% both without surveil-
lance and with one surveillance visit, falling to 3% with two 
visits. High- risk patients might therefore benefit from attending 
two surveillance visits, although studies are needed to define 
the optimum interval between first and second visits. When we 
stratified the high- risk group into subgroups, estimates were too 
imprecise to draw clear conclusions.
Our findings suggest that surveillance is warranted for 
high- risk patients (n=2719) and the higher- risk subgroup of 
intermediate- risk patients (n=7114) (34% of our cohort), but 
not for the lower- risk subgroup of intermediate- risk patients 
(n=4738) or low- risk patients (n=14 401) (66% of our cohort), 
who could instead be managed by screening. In the BCSP in 
England, surveillance is recommended for intermediate- risk 
and high- risk patients only.23 In this setting, numbers of surveil-
lance colonoscopies could be reduced by a third if the lower- risk 
subgroup of intermediate- risk patients forewent surveillance.
Patients returning to the BCSP would be screened bienni-
ally with the faecal immunochemical test (FIT), which replaced 
the faecal occult blood test in June 2019.24 Although FIT was 
introduced with a relatively high positivity threshold of 120 µg 
haemoglobin per gram of faeces, the threshold may be lowered 
over time if endoscopy capacity increases, which would improve 
FIT sensitivity for adenomas and early CRCs.25 It is important 
that patients returning to screening are reminded to see their 
general practitioner if lower gastrointestinal symptoms occur.
Several baseline characteristics were repeatedly predictive of 
CRC, including older age, incomplete colonoscopies, adenomas 
with high- grade dysplasia and proximal polyps. This aligns with 
our previous study of intermediate- risk patients,13 16 and other 
studies describing these as risk factors for incident advanced 
neoplasia.26 27 These findings reinforce the importance of a thor-
ough baseline colonoscopy with complete resection of detected 
lesions. Incomplete resection might be implicated in the elevated 
risk among patients with high- grade dysplasia or proximal polyps, 
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Figure 3 Cumulative colorectal cancer incidence after baseline in the intermediate- risk group. 
Cumulative colorectal cancer incidence with no surveillance (censoring at first surveillance) for the whole intermediate- risk group (A) and the lower- 
risk and higher- risk subgroups (B). Cumulative colorectal cancer incidence after a single surveillance visit (censoring at second surveillance) for the 
whole intermediate- risk group (C) and the lower- risk and higher- risk subgroups (D). 95% CIs are shown for each curve. The higher- risk subgroup 
included patients with an incomplete colonoscopy or colonoscopy of unknown completeness, an adenoma with high- grade dysplasia or proximal 
polyps at baseline; the lower- risk subgroup included patients with none of these factors.
as advanced and proximal polyps have been associated with greater 
risks of incomplete resection.28 Some proximal polyps in our study 
may have been serrated lesions which are often proximally located, 
flat, and difficult to see and remove.29 Unfortunately, serrated 
lesions were not consistently classified in the era of our data.
Half of low- risk patients, 60% of intermediate- risk patients 
and 66% of high- risk patients attended surveillance. Non- 
attenders were older than attenders, more likely to have had 
an incomplete baseline colonoscopy or poor bowel prepara-
tion, and in the intermediate- risk group were more likely to 
be female, consistent with the literature.13 16 30 That 30%–40% 
of intermediate- risk and high- risk patients had no surveillance 
suggests some underuse of surveillance colonoscopy. Unfortu-
nately, we had no information on why patients did not attend 
surveillance, but reasons may have included patient comorbidi-
ties, objections to colonoscopy or process errors.
Among low- risk patients, first surveillance occurred after a 
median of 3.2 years, earlier than recommended.3 This has been 
observed elsewhere.31 32 Possible explanations include slow 
adoption of guidelines and concern about postcolonoscopy 
CRCs. There was greater adherence to recommended surveil-
lance intervals for intermediate- risk and high- risk patients.
Besides the present study and our previous study of intermediate- 
risk patients,13 16 only one other study has compared CRC risk 
following adenoma removal with that in the general population 
in the absence and presence of surveillance.17 This study included 
5779 patients who underwent baseline colonoscopy from 1990 
to 1999. Among patients with an AA (adenoma ≥10 mm, with 
high- grade dysplasia or villous histology) at baseline, CRC risk 
without surveillance was four times that in the general population 
and surveillance substantially reduced this risk. By contrast, among 
patients with non- AAs, CRC risk without surveillance was similar 
to in the general population and surveillance did not affect CRC 
risk. The study was limited, however, by the small sample size and 
age of the data.
Strengths of the present study include the large, high- quality 
data set, comprising detailed data from 17 hospitals on baseline 
and surveillance colonoscopies. The hospitals included general 
and teaching hospitals located throughout the UK. Few data were 
missing and follow- up was complete for nearly all patients. Most 
baseline colonoscopies were performed after the introduction of 
colonoscopy quality initiatives in 2001.11 Nevertheless, 20% of 
patients did not have a complete baseline colonoscopy. Exclusion 
of these patients had little impact, however, indicating that the find-
ings are applicable in the modern era of high- quality colonoscopy.
Limitations include the observational design, meaning we cannot 
assume that surveillance caused the reductions in CRC incidence. 
However, we adjusted for potential confounders and still saw a 
large effect of surveillance on incidence. Use of routine data means 
that misclassification may have occurred; however, this would 
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Figure 4 Cumulative colorectal cancer incidence after baseline in the high- risk group. 
Cumulative colorectal cancer incidence with no surveillance (censoring at first surveillance) for the whole high- risk group (A) and the lower- risk and 
higher- risk subgroups (B). Cumulative colorectal cancer incidence after a single surveillance visit (censoring at second surveillance) for the whole 
high- risk group (C) and the lower- risk and higher- risk subgroups (D). 95% CIs are shown for each curve. The higher- risk subgroup included patients 
with an incomplete colonoscopy or colonoscopy of unknown completeness or an adenoma with high- grade dysplasia at baseline; the lower- risk 
subgroup included patients with none of these factors.
likely be non- differential, producing underestimations of effects. 
More patients attending surveillance were missing baseline data 
than non- attenders, particularly for colonoscopy completeness 
and bowel preparation quality, which is a potential source of bias. 
Some follow- up colonoscopies may have been for symptoms rather 
than surveillance. Additionally, as patients were stratified into risk 
groups by baseline adenoma size and number, we could not inter-
pret the individual effects of these characteristics. Finally, although 
the follow- up period was long, the full benefit of surveillance on 
CRC incidence may not manifest until after 10 years.
COnCluSIOn
A large proportion of patients with adenomas do not remain at 
increased CRC risk following a complete baseline colonoscopy 
and polypectomy, compared with the general population. In our 
cohort, this was true for low- risk patients, and intermediate- 
risk patients without high- grade dysplasia or proximal polyps. 
Surveillance is probably not necessary for these patients and 
routine screening would suffice, although patients should be 
reminded to contact their general practitioner if lower gastro-
intestinal symptoms occur. Conversely, surveillance is warranted 
for high- risk patients, and intermediate- risk patients without 
a complete baseline colonoscopy or with high- grade dysplasia 
or proximal polyps, whose risk was higher than in the general 
population before surveillance. Incorporating these findings into 
guidelines could reduce surveillance colonoscopies by a third, 
while ensuring that patients at increased risk are protected.
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